Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

AI Briefing

• – Amplia Therapeutics reports positive trial results for pancreatic cancer drug narmafotinib, with median overall survival of 11.1 months.
• – The ACCENT clinical trial also showed four complete responses in patients with advanced pancreatic cancer.
• – Amplia Therapeutics to continue evaluating narmafotinib in ongoing trials with additional data expected in the future.